Company intelligence / Profile preview

IgNova

Visbek, Niedersachsen, Germanyignovamech.com ↗

Ownership: Private
Employees: ~1
Development stage: Other

Overview

IgNova has developed a proprietary platform for producing polyclonal antibodies (IgY) from chicken eggs, targeting pathogens such as SARS-CoV-2. Their lead program involves passive immunization against COVID‑19 by neutralizing the virus at mucosal surfaces. As of mid‑2020, they had filed a patent and were in final research stages with initial testing underway; no published clinical results or regulatory approvals have been reported.

Therapeutic areas: Infectious Diseases
Modalities: Polyclonal antibody (specifically, Immunoglobulin Y/IgY)Antibody (general)
Industry: Biotech

Partnerships

No specific major pharmaceutical partnerships named; company states it works closely with scientific institutions and potential strategic partners to bring products to market

Beyond the preview

Go deeper on IgNova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgNova.

Explore the full profile